GSK-2239633

CAS No. 2181665-31-4

GSK-2239633( GSK2239633 )

Catalog No. M13483 CAS No. 2181665-31-4

GSK-2239633 is a potent, selective, allosteric CCR4 antagonist with pIC50 of 7.96.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 963 Get Quote
50MG 1962 Get Quote
100MG 2520 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    GSK-2239633
  • Note
    Research use only, not for human use.
  • Brief Description
    GSK-2239633 is a potent, selective, allosteric CCR4 antagonist with pIC50 of 7.96.
  • Description
    GSK-2239633 is a potent, selective, allosteric CCR4 antagonist with pIC50 of 7.96; also inhibits TARC-induced increases in the F-actin content of isolated human CD4+ CCR4+ T-cells with pA2 of 7.1.Asthma Phase 1 Clinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    GSK2239633
  • Pathway
    GPCR/G Protein
  • Target
    Chemokine Receptor
  • Recptor
    Chemokine Receptor
  • Research Area
    Inflammation/Immunology
  • Indication
    Asthma

Chemical Information

  • CAS Number
    2181665-31-4
  • Formula Weight
    506.976
  • Molecular Formula
    C21H19ClN4O5S2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NC1=CC=CC(CN2N=C(NS(=O)(C3=CC=C(Cl)S3)=O)C4=C2C=CC=C4OC)=C1)CO
  • Chemical Name
    N-(3-((3-((5-chlorothiophene)-2-sulfonamido)-4-methoxy-1H-indazol-1-yl)methyl)phenyl)-2-hydroxyacetamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Cahn A, et al. BMC Pharmacol Toxicol. 2013 Feb 28;14:14. 2. Procopiou PA, et al. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2730-3.
molnova catalog
related products
  • (S)-CCX-777

    A small-molecule partial agonist of CXCR7 (ACKR3).

  • KRH-3955

    A potent, selective, orally bioavailable inhibitor of CXCR4 that efficiently inhibits SDF-1α binding to CXCR4 with IC50 of 0.61 nM.

  • SX-576

    A potent, equipotent CXCR1 and CXCR2 antagonist with IC50 of 31 nM and 21 nM, respectively.